Sironax announced a strategic agreement with Novartis (NVS) under which Sironax will grant Novartis an exclusive option to acquire its proprietary Brain Delivery Module, BDM, platform, a differentiated blood-brain-barrier, BBB, crossing technology designed to enhance the brain delivery of therapeutics of various modalities. Sironax retains the right to continue developing selected therapeutic assets using the platform. “This partnership combines Novartis’s global expertise in neuroscience with Sironax’s high-quality innovation, maximizing the potential impact of our brain delivery platform,” said Dr. Shefali Agarwal, President and CEO of Sironax. “At the same time, we will continue to explore our targets of interest with the platform and deliver brain-penetrant therapeutics. This strategic alignment empowers Sironax to accelerate its global expansion and clinical development, reinforcing our commitment to redefining what’s possible for patients living with serious neurological conditions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis (NVS) Wins Landmark Approval for Baby Malaria Treatment
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Drugmakers criticize Trump drug price negotiation plan, Bloomberg reports
- Pharma cos criticize Trump’s drug price negotiation plan, Bloomberg Law reports
- Novartis announces Coartem Baby approved by Swissmedic